Effects of Egg White Protein Supplementation on Muscle Strength and Serum Free Amino Acid Concentrations

The aim of this study was to evaluate the effects of egg white protein compared to carbohydrate intake prior to exercise on fat free mass (FFM), one repetition maximum (1RM) muscle strength and blood biochemistry in female athletes. Thirty healthy female collegiate athletes were recruited for this study and matched by sport type, body fat percentage and 1RM leg curl muscle strength. Participants were randomly divided into two groups: protein group (15.0 g egg white protein; 75 kcal) and carbohydrate group (17.5 g maltodextrin, 78 kcal). Supplements were administered daily at the same time in a double-blind manner prior to training during an 8-week period. Measurements were performed before and after the 8-week regimen. The mean dietary energy intake did not change throughout the study period. FFM and 1RM assessments (i.e., leg curl, leg extension, squat, and bench press) increased in both groups. Furthermore, serum urea and serum citrulline levels after the 8-week regimen increased significantly only in the protein group. Our findings indicated that compared to the carbohydrate supplement, the protein supplement was associated with some changes in protein metabolites but not with changes in body composition or muscle strength

Complete Genome Sequence of Canine Papillomavirus Type 11

Papillomaviruses with the features of epitheliotropic, nonenveloped, circular, and double-stranded DNA belong to the family Papillomaviridae, which contributes to benign and malignant tumors in humans and animals. We report the whole-genome sequence of canine papillomavirus type 11 found at a pigmented plaque located on the skin of a mixed-breed bloodhound

Combination of Octreotide and Oral Glucose Maintains the Blood Glucose Level and Improves Survival Rate in Rats after Monochloroacetic Acid Exposure

We report the combined therapeutic effect of subcutaneous injection of octreotide and oral glucose administration to monochloroacetic acid exposed rats. The control rats group was subcutaneously injected with 80 mg/kg sodium monochloroacetate and infused with 2 mL/hour 10% glucose solution for 10 hours 60 minutes after exposure. Group A was given 2 g/kg oral glucose after exposure, and then infused with glucose as control. Group B was given 2 g/kg oral glucose and a subcutaneous injection of 30 µg/kg octreotide after exposure, and then infused with glucose as control. The 14-day survival rate was 0.35 (control), 0.50 (group A) and 0.90 (group B). The blood glucose of group B increased to 188 mg/dl at the beginning of the glucose infusion, significantly higher than group A. Although there were significant differences in the lactate levels between the 3 groups, the levels were not abnormally high. In conclusion, our study suggests that it is important to elevate the blood glucose levels within 60 minutes after monochloroacetic acid exposure. In addition, a combination of subcutaneous octreotide and oral glucose is advantageous to maintain high blood glucose level at early stages after exposure and may be an effective therapy for monochloroacetic acid intoxication

Complete Genome Sequence of Canine Papillomavirus Virus Type 12

Papillomaviruses, of the family Papillomaviridae, are epitheliotropic, nonenveloped, circular, double-stranded DNA viruses that contribute to benign and malignant tumors in humans and animals. We report here the whole-genome sequence of canine papillomavirus type 12, found at a pigmented plaque located on the skin of a mixed-breed bloodhound

Complete Genome Sequence of Canine Papillomavirus Virus Type 12

Papillomaviruses, of the family Papillomaviridae, are epitheliotropic, nonenveloped, circular, double-stranded DNA viruses that contribute to benign and malignant tumors in humans and animals. We report here the whole-genome sequence of canine papillomavirus type 12, found at a pigmented plaque located on the skin of a mixed-breed bloodhound

Effective Functional Immunogenicity of a DNA Vaccine Combination Delivered via In Vivo Electroporation Targeting Malaria Infection and Transmission

circumsporozoite protein (PfCSP) and Pfs25 are leading candidates for the development of pre-erythrocytic and transmission-blocking vaccines (TBV), respectively. Although considerable progress has been made in developing PfCSP- and Pfs25-based vaccines, neither have elicited complete protection or transmission blocking in clinical trials. The combination of antigens targeting various life stages is an alternative strategy to develop a more efficacious malaria vaccine. In this study, female and male mice were immunized with DNA plasmids encoding PfCSP and Pfs25, administered alone or in combination via intramuscular in vivo electroporation (EP). Antigen-specific antibodies were analyzed for antibody titers, avidity and isotype by ELISA. Immune protection against sporozoite challenge, using transgenic expressing PfCSP and a GFP-luciferase fusion protein (PbPfCSP-GFP/Luc), was assessed by in vivo bioluminescence imaging and blood-stage parasite growth. Transmission reducing activity (TRA) was evaluated in standard membrane feeding assays (SMFA). High levels of PfCSP- and Pfs25-specific antibodies were induced in mice immunized with either DNA vaccine alone or in combination. No difference in antibody titer and avidity was observed for both PfCSP and Pfs25 between the single DNA and combined DNA immunization groups. When challenged by PbPfCSP-GFP/Luc sporozoites, mice immunized with PfCSP alone or combined with Pfs25 revealed significantly reduced liver-stage parasite loads as compared to mice immunized with Pfs25, used as a control. Furthermore, parasite liver loads were negatively correlated with PfCSP-specific antibody levels. When evaluating TRA, we found that immunization with Pfs25 alone or in combination with PfCSP elicited comparable significant transmission reduction. Our studies reveal that the combination of PfCSP and Pfs25 DNAs into a vaccine delivered by in vivo EP in mice does not compromise immunogenicity, infection protection and transmission reduction when compared to each DNA vaccine individually, and provide support for further evaluation of this DNA combination vaccine approach in larger animals and clinical trials